Is sacral nerve modulation reprogramming effective after permanent implantation for faecal incontinence?

AIM: Sacral nerve modulation (SNM) is recommended as a first-line surgical therapy for patients with faecal incontinence (FI). During patient follow-up, it is recommended that stimulation settings be reprogrammed to optimize patient outcomes. The aim of the present study was to evaluate the efficacy of stimulator reprogramming in patients with an implanted SNM device to treat FI. METHOD: The data from patients who received a permanent SNM implant in a single centre from January 2008 to December 2019 were retrospectively analysed. Symptoms that occurred after implantation, the stimulator settings of the SNM device and changes made at each follow-up visit were noted. The efficacy of reprogramming was determined by assessing patient satisfaction. RESULTS: Of the 117 patients (male/female 4/113; mean age 59.5 ± 11.8 years) with a SNM implant for FI, 84 (72%) had at least one symptom requiring reprogramming of the stimulator, most often during the first year after implantation (p = 0.05). The most frequently reported symptoms were loss of efficacy (68.5%; p = 1 × 10-3 ) and pain (20.5%; p = 1 × 10-3 ). Reprogramming was effective 53% of the time when treating loss of efficacy and 76% of the time when treating pain. When the stimulation parameters were reprogrammed at least four consecutive times to correct a symptom, the reprogramming was less effective in treating the symptom (p = 0.02). CONCLUSION: Regular follow-up of patients with SNM device implants associated with reprogramming of stimulation parameters to improve the treatment of reported symptoms would optimize the efficacy of SNM.

Effects of intragastric L-arginine administration on proximal stomach tone under basal conditions and after an intragastric diet.

Nitric oxide (NO) plays an important role as a nonadrenergic, noncholinergic inhibitory neurotransmitter in the GI tract. Our study aims were to investigate the effect of a single intragastric L-arginine (L-Arg) administration, as a source of NO, on proximal stomach tone in basal and postintragastric administration of a polymeric diet in humans and to evaluate concomitantly the effect on antral area as an indirect assessment of gastric emptying. Eight healthy volunteers were studied in a randomized double-blind crossover study after, respectively, 15 g L-Arg, 30 g L-Arg, or placebo administered in the stomach through a gastric tube. The drug administration was followed by a polymeric diet infusion (500 ml/500 kcal) at a rate of 250 ml/hr. Gastric tone variations were recorded with an electronic barostat, gastric emptying was concomitantly estimated by repeated ultrasound measurements of antral area, and symptoms were recorded throughout the experiment.L-Arg administration was associated with significantly higher increases in barostat bag volumes at both dosages, 30 g (117+/-16 ml) and 15 g (67+/-15 ml), compared to placebo (46+/-11 ml; P < 0.05). In response to the polymeric diet the 30-g L-Arg challenge was associated with a smaller increase in intrabag volume, whereas postinfusion final volumes did not differ in the three treatment conditions. Antral areas were not different at any time of measurement among the three challenges. Bloating and diarrhea were observed after 30-g L-Arg administration in five subjects of eight. Short-term L-Arg administration was able to induce proximal stomach relaxation that allowed a secondary response to enteral feeding only at the 15-g dosage. This 15-g dosage was as well tolerated as the placebo and was associated with no significant changes in gastric emptying patterns.

Concomitant variations of gastric tone and duodenal motility in humans: results of a placebo-controlled study assessing octreotide and sumatriptan.

OBJECTIVE: To describe the concomitant effects of octreotide and sumatriptan on fundic tone and duodenal phase III activity. MATERIAL AND METHODS: A double-blind study was performed in nine volunteers, studied for 2 h after receiving 50 microg octreotide, 6 mg sumatriptan or placebo. Fundic tone variations were assessed by barostat while antroduodenal motility was studied concomitantly using manometry. RESULTS: A rapid increase in intrabag volume was observed in all but one subject after both sumatriptan and octreotide administration, while only two subjects exhibited a volume variation after placebo, p<0.01. A significant decrease in the number of phasic contractions was observed after octreotide, while sumatriptan reduced only wave amplitudes (p<0.05). A total of 13 concomitant duodenal phase III-like activities were observed in the duodenum after octreotide, 3 after sumatriptan and 4 after placebo, all followed by spontaneous fundic relaxation with disappearance of phasic contractions, p<0.05. Spontaneous phase III activities were different from phases III-like activities after octreotide in velocity and duration (p<0.05). CONCLUSIONS: Octreotide induced concomitant fundic relaxation, disappearance of phasic contractions and duodenal phase III-like activity. Sumatriptan relaxed the proximal stomach and reduced the amplitude of fundic phasic contractions without affecting concomitant antroduodenal phase III activity.